Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients.

TitleAcute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients.
Publication TypeJournal Article
Year of Publication2022
AuthorsMcNerney KO, Oranges K, Seif AE, Oshrine B, Ky B, Lin KY, Getz KD, Aplenc R
JournalJ Pediatr Hematol Oncol
Volume44
Issue2
Paginatione507-e511
Date Published2022 Mar 01
ISSN1536-3678
Abstract

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody-tumor antibiotic conjugate with proven efficacy in pediatric and adult patients with CD33+ acute myeloid leukemia. Adverse effects commonly associated with GO include hyperbilirubinemia, elevated transaminases, and sinusoidal obstruction syndrome. Cardiotoxicity has not been a commonly described adverse event. We describe 2 pediatric patients with relapsed/refractory acute myeloid leukemia who received fractionated GO monotherapy and subsequently developed severe acute left ventricular dysfunction. Both patients achieved remission, recovered cardiac function with medical therapy, and tolerated subsequent stem cell transplantation.

DOI10.1097/MPH.0000000000002325
Alternate JournalJ Pediatr Hematol Oncol
PubMed ID35200224
PubMed Central IDPMC8873989
Grant ListK01 HL143153 / HL / NHLBI NIH HHS / United States